Search results
Your search for Orgran returned no results
Showing 16 to 30 of 318 results for organ
Showing 16 to 30 of 318 results for organ
into the vagina and left in place to support the vaginal walls and pelvic organs. If you have tried to manage your condition without...
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
Suspected sepsis: recognition, diagnosis and early management
pregnant): source control rapid antigen tests for sepsis indicators of organ hypoperfusion intravenous fluids vasopressors. For all...
If your mesh was for pelvic organ prolapse, see NICE's decision aid on treating complications from mesh used for pelvic...
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
into the vagina and left in place to support the vaginal walls and pelvic organs. If you have tried to manage your condition without...
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09
In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death
In development Reference number: GID-IPG10405 Expected publication date: TBC
Immunosuppressive therapy for kidney transplant in adults (TA481)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).